Skip to main content Back to Top
Advertisement

9/15/2025

Ibandronate Sodium Injection

Products Affected - Description

    • Ibandronate sodium intravenous solution for injection, Apotex, 1 mg/mL, 3 mL prefilled syringe, NDC 60505-6097-00
    • Ibandronate sodium intravenous solution for injection, Eugia US, 1 mg/mL, 3 mL prefilled syringe, NDC 55150-0191-83

Reason for the Shortage

    • Apotex did not provide a reason for the shortage.
    • Eugia did not provide a reason for the shortage.
    • Viatris discontinued ibandronate prefilled syringes in December 2024.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Apotex has ibandronate 1 mg/mL 3 mL prefilled syringes on back order and the company estimates a release date of mid-November 2025.
    • Eugia has ibandronate 1 mg/mL 3 mL prefilled syringes on intermittent back order and the company is releasing supplies as they become available. Short-dated product is available (May 2026).

Updated

Created September 15, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT